Hafzalla GW, Abramov D, Shapiro MD, Minhas AMK. A comparative analysis of cardiovascular disease mortality trends attributable to risk factors in the United States and globally from 1990 to 2019: an analysis of the global burden of disease study 2019. Am J Prev Cardiol. 1990;101064:101064.

Google Scholar 

Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. JACC. Elsevier; 2026.

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:e285-350 (American College of Cardiology Foundation Washington DC).

Article  PubMed  Google Scholar 

Zhang Y, Woo JG, Urbina EM, Jacobs DR Jr, Moran AE, De Ferranti SD. Low-density lipoprotein cholesterol trajectories and prevalence of high low-density lipoprotein cholesterol consistent with heterozygous familial hypercholesterolemia in US children. JAMA Pediatr. 2021;175:1071–4.

Article  PubMed  PubMed Central  Google Scholar 

Brautbar A, Leary E, Rasmussen K, Wilson DP, Steiner RD, Virani S. Genetics of familial hypercholesterolemia. Curr Atheroscler Rep. 2015;17:20 (Springer).

Article  Google Scholar 

Kronenberg F, Mora S, Stroes ES, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925–46 (Oxford University Press US).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bess C, Mehta A, Joshi PH. All we need to know about lipoprotein (a). Prog Cardiovasc Dis Elsevier. 2024;84:27–33.

Google Scholar 

De Oliveira-Gomes D, Joshi PH, Peterson ED, Rohatgi A, Khera A, Navar AM. Apolipoprotein B: bridging the gap between evidence and clinical practice. Circulation. 2024;150:62–79 (Lippincott Williams & Wilkins Hagerstown, MD).

Article  PubMed  PubMed Central  Google Scholar 

Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77:1439–50 (American College of Cardiology Foundation Washington DC).

Article  CAS  PubMed  Google Scholar 

Luebbe S, Sniderman AD, Moran AE, Wilkins JT, Kohli-Lynch CN. Cost-effectiveness of apoB, non–HDL-C, and LDL-C goals for primary prevention lipid-lowering therapy. JAMA. 2026;335:1507–14 (American Medical Association).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med. 2012;172:1707–10 (American Medical Association).

Article  CAS  PubMed  Google Scholar 

Langsted A, Freiberg J, Tybjærg-Hansen A, Schnohr P, Jensen GB, Nordestgaard B. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen city heart study with 31 years of follow-up. J Intern Med. 2011;270:65–75.

Article  CAS  PubMed  Google Scholar 

Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and validation of the American heart association’s PREVENT equations. Circulation. 2024;149:430–49 (Lippincott Williams & Wilkins Hagerstown, MD).

Article  PubMed  Google Scholar 

Abdul Jabbar AB, Inam M, Butt N, Khan SS, Sheikh S, Khoja A, et al. Predicting risk of cardiovascular disease EVENTs (PREVENT) equations: what clinicians need to know? Curr Atheroscler Rep. 2025;27:73 (Springer).

Article  CAS  PubMed  Google Scholar 

Mathew RO, Khan SS, Tuttle KR, Ho JE, Abramov D, Bangalore S, et al. Performance of the American heart association’s PREVENT risk score for cardiovascular risk prediction in a multiethnic population. Nat Med. 2025;31:2655–62 (Nature Publishing Group US New York).

Article  CAS  PubMed  Google Scholar 

Hong C, Niu M, Wang H, Wojdyla DM, Economou-Zavlanos N, Engelhard MM, et al. Performance of PREVENT cardiovascular risk in electronic health record-based clinical practice. JAMA Netw Open. 2026;9:e266838 (American Medical Association).

Article  PubMed  PubMed Central  Google Scholar 

Minhas AMK, Virani SS, Michos ED, Nambi V, Blumenthal RS, Razavi AC, et al. Comparing cardiovascular risk classification of US adults according to pooled cohort equations and PREVENT equations: cross-sectional analysis of the national health and nutrition examination survey. Ann Intern Med. 2024;177:1444–8 (American College of Physicians).

Article  PubMed  Google Scholar 

Razavi AC, Agatston AS, Shaw LJ, De Cecco CN, van Assen M, Sperling LS, et al. Evolving role of calcium density in coronary artery calcium scoring and atherosclerotic cardiovascular disease risk. JACC Cardiovasc Imaging. 2022;15:1648–62.

Article  PubMed  PubMed Central  Google Scholar 

Bell KJ, White S, Hassan O, Zhu L, Scott AM, Clark J, et al. Evaluation of the incremental value of a coronary artery calcium score beyond traditional cardiovascular risk assessment: a systematic review and meta-analysis. JAMA Intern Med. 2022;182:634–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Budoff MJ, Kinninger A, Gransar H, Achenbach S, Al-Mallah M, Bax JJ, et al. When does a calcium score equate to secondary prevention? Insights from the multinational CONFIRM registry. Cardiovasc Imaging. 2023;16:1181–9 (American College of Cardiology Foundation Washington DC).

Google Scholar 

Orringer CE, Blaha MJ, Blankstein R, Budoff MJ, Goldberg RB, Gill EA, et al. The national lipid association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J Clin Lipidol. 2021;15:33–60.

Article  PubMed  Google Scholar 

Laffin LJ, Bruemmer D, Garcia M, Brennan DM, McErlean E, Jacoby DS, et al. Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers. J Am Coll Cardiol. 2023;81:1–12.

Article  CAS  PubMed  Google Scholar 

Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120:229–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2022;328:754–71.

Article  PubMed  Google Scholar 

Xie M, Martin SS, Turchin A. Reasons for non-acceptance of statin therapy by patients at high cardiovascular risk. Sci Rep. 2025;15:17014 (Nature Publishing Group UK London).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grundy SM, Vega GL. Statin intolerance and noncompliance: an empiric approach. Am J Med. 2022;135:318–23.

Article  CAS  PubMed  Google Scholar 

Schleyer T, Hui S, Wang J, Zhang Z, Knapp K, Baker J, et al. Quantifying unmet need in statin-treated hyperlipidemia patients and the potential benefit of further LDL-C reduction through an EHR-based retrospective cohort study. J Manag Care Spec Pharm. 2019;25:544–54 (Academy of Managed Care Pharmacy).

PubMed  PubMed Central  Google Scholar 

Lowenstern AM, Li S, Navar AM, Roger VL, Robinson JG, Goldberg AC, et al. Measurement of low‐density lipoprotein cholesterol levels in primary and secondary prevention patients: insights from the PALM registry. J Am Heart Assoc. 2018;7:e009251.

Article  PubMed  PubMed Central  Google Scholar 

Mansoor T, Nambi V, Parikh S, Misra A, Ismayl M, Sullivan C, et al. Targeting triglycerides: the rise of Apolipoprotein C3 and Angiopoietin-Like protein 3 inhibitors: T. Mansoor et al. Am J Cardiovasc Drugs. 2025;25:749–66 (Springer).

Article  PubMed  Google Scholar 

Mahtta D, Rodriguez F, Jneid H, Levine GN, Virani SS. Improving adherence to cardiovascular guidelines: realistic transition from paper to patient. Expert Rev Cardiovasc Ther. 2020;18:41–51 (Taylor & Francis).

Article  CAS  PubMed  Google Scholar